Chief Executive Officer
Dr. Velleca joined G1 as chief executive officer in 2014. Previously, he was at CGI Pharmaceuticals, where he guided the company from its inception through its establishment as a drug discovery company that brought multiple drug candidates into clinical trials. After CGI was acquired by Gilead Sciences, Dr. Velleca served as a senior advisor to Gilead in R&D Strategy and Corporate Development. Earlier in his career, Dr. Velleca was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.
Dr. Velleca earned a BS from Yale University and an MD and PhD from Washington University in St. Louis. He has served on the board of directors and scientific advisory boards of several biotechnology companies, including Intellikine, an oncology therapeutics company that was acquired by Takeda in 2011. He most recently served as executive vice president at The Leukemia & Lymphoma Society.
Chief Medical Officer
Dr. Malik joined G1 as chief medical officer in 2014. Most recently, he served as chief medical officer and management board member at Agennix AG, where he was responsible for research and development. Prior to Agennix AG, he served as chief medical officer at Adherex Technologies, where he directed the company's global regulatory strategy and clinical development programs. Dr. Malik also served in oncology clinical development positions at EMD Pharmaceuticals and Bristol-Myers Squibb.
Dr. Malik received his MD from the University of Sheffield Medical School in the U.K. He completed his residency at Duke University Medical Center and fellowships at Children's Hospital of Philadelphia and Duke University Medical Center. During his academic career, he was an assistant professor at the University of Virginia, where he conducted basic science and clinical research in addition to patient care and teaching.
Chief Business Officer
Mr. Mossinghoff joined G1 as chief business officer in 2014. Most recently, he served as president of Integrated Oncology Solutions and Inspire Pharmaceuticals, and helped guide Inspire from its early stages of development through its IPO. In his first decade in the industry, Mr. Mossinghoff held various management positions of increasing responsibility at Roche and GlaxoWellcome in global business development, new product planning, finance and operations. As a senior executive and board member of several biopharmaceutical companies, he has experience in strategic planning, technology valuation, partnering, capital markets and fundraising.
Mr. Mossinghoff holds an MBA in financial management and analysis from George Mason University and a BA in economics from the University of Virginia.
Chief Scientific Officer
Dr. Strum joined G1 as its first employee and founding chief scientific officer. He was instrumental in building the kinase drug discovery platform at G1 and recruiting, leading and managing the R&D team. Prior to G1, Dr. Strum was at GlaxoSmithKline (GSK) where he led drug discovery programs in cancer and metabolic diseases that brought multiple drug candidates into clinical development. He also played a key role in establishing and driving genomics research at GSK through the creation and management of an international gene expression department that included a human tissue repository and a human adipose-derived stem cell laboratory.
Dr. Strum obtained his PhD in biochemistry from Wake Forest University and did postdoctoral work with Dr. Bob Bell in molecular cancer biology at Duke University. His broad multidisciplinary experience in research and development includes being an author on more than 40 scientific papers, three book chapters and an inventor/co-inventor on 18 patents.